Stem Cell/Cord Blood Banking Global Market Report 2024

The stem cell/cord blood banking market size has grown strongly in recent years. It will grow from $11.14 billion in 2023 to $12.19 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The expansion observed during the historical period can be attributed to factors such as significant advancements in medical science, heightened awareness, successful clinical applications, regulatory support, and increased funding for research in the field of stem cell and cord blood banking.

The stem cell/cord blood banking market size is expected to see rapid growth in the next few years. It will grow to $18.83 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to the rise of personalized medicine, the emergence of novel therapies, international expansion efforts, increased investments in biotechnology, and the establishment of legal and ethical frameworks. Notable trends expected during the forecast period include the development of non-invasive collection methods, the diversification of banking services, a focus on transparency and regulatory compliance, collaborative initiatives, and innovations in storage technologies.

The increasing number of cancer patients is a major driving force for the stem cell/cord blood banking market. Diseases like leukemia and multiple myeloma, which are forms of cancer, can be treated through stem cell transplantation. Stem cell transplants can be autologous, using stem cells from the patient, or allogeneic, where stem cells come from a matched donor, either related or unrelated. Stem cell transplantation helps restore blood-forming stem cells damaged during chemotherapy. In 2021, cancer led to the deaths of 10 million people worldwide, and stem cell transplants offer potential treatments for these conditions.

The primary cell types involved in stem cell and cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a relatively rare group of cells found in the body during most of postnatal life. They have the capacity to generate a limited number of mature cell types specific to the tissue in which they are located. The various services provided in this field encompass collection, processing, analysis, and storage. These services are offered by different types of banks, including private banks and public banks. The applications for stem cell and cord blood banking are diverse and include conditions such as leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, and many others.

The stem cell/cord blood banking market research report is one of a series of new reports that provides stem cell/cord blood banking market statistics, including stem cell/cord blood banking industry global market size, regional shares, competitors with a stem cell/cord blood banking market share, detailed stem cell/cord blood banking market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell/cord blood banking industry. This stem cell/cord blood banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rising prevalence of chronic diseases is expected to fuel the growth of the stem cell/cord blood banking market in the future. Chronic diseases are long-lasting illnesses that can worsen over time, often lacking effective treatments. Stem cells and cord blood are increasingly explored for their regenerative potential in treating chronic conditions. Stem cell transplants, personalized medicine, and clinical research into novel therapies for chronic diseases are on the rise, leading to a higher demand for banking services. According to the National Center for Biotechnology Information (NCBI), the number of people with chronic diseases worldwide is projected to reach 142.66 million by 2050, up from 71.522 million in 2020, highlighting the growing need for these services.

Lack of awareness, particularly among pregnant women, poses a significant restraint for the stem cell/cord blood banking market. Many pregnant women are unaware of how public cord blood banks function, leading to underutilization of the advantages of stem cell transplantation in cancer treatment. For example, a survey published in the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology (IJRCOG) revealed that only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy. Moreover, just 5% were aware of the procedure's cost, and less than 1% knew about the availability of cord blood banking.

An emerging trend in the stem cell/cord blood banking market is the pairing of cord blood and tissue storage with genetic testing services. This pairing offers complimentary services to existing clients, expanding their product portfolios. For instance, genetic testing company Natera introduced the Evercord cord blood and tissue storage service, enabling expectant parents to collect, store, and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications.

Major companies operating in the stem cell/cord blood banking market are developing peripheral blood stem cell processing and storage services to gain a competitive advantage. This involves the collection, processing, testing, and cryopreservation of hematopoietic stem cells (HSCs) obtained from a patient's peripheral blood. Cordlife Group Limited, a Singapore-based healthcare company, launched a new peripheral blood stem cell (PBSC) processing and storage service in Singapore in February 2023. This service supports patients requiring hematopoietic stem cell transplantation for various blood-related diseases, including leukemia, myeloma, and lymphoma. Cordlife collaborates with the Centre for Clinical Hematology (CFCH) to offer eligible patients stem cell mobilization and harvesting, with Cordlife handling the subsequent processing, testing, and cryopreservation of PBSCs. This new service aims to improve treatment outcomes for individuals requiring hematopoietic stem cell transplants in Singapore.

In December 2021, Cooper Companies, a U.S.-based medical device company, acquired Generate Life Sciences for $1.66 billion. This acquisition enhances Cooper & Co.'s ability to serve consumers and expand their customer base. Generate Life Sciences is a U.S.-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage (cord blood and cord tissue) services.

Major companies operating in the stem cell/cord blood banking market include AMAG Pharmaceuticals Inc., Cryo-Cell International Inc., Esperite NV, Americord Registry LLC, China Cord Blood Corporation, Cordlife Group Ltd., CordVida, Cryo Stemcell, PerkinElmer Inc., ReeLabs Pvt Ltd., Smart Cells International Ltd., Stemade Biotech Pvt Ltd., ViaCord Inc., Americord Registry LLC, LifeCell International, Cryoviva Biotech Pvt Ltd., Cytori Therapeutics Inc., Thermo Fisher Scientific Inc., Cord Blood America Inc., StemCyte Inc., Brainstorm Cell Therapeutics Inc., Cord Blood Registry Systems Inc., Healthbanks Biotech Usa Inc., Cryo-save Private Ltd., New York Cord Blood Center, CryoHoldco, Vita 34 International AG, Reliance Life Sciences Pvt Ltd., Maze Cord Blood Laboratories, Cells4Life Group LLP

North America was the largest region in the stem cell/cord blood banking market in 2023. Western Europe was the second largest region in the stem cell/cord blood banking market analysis. The regions covered in the stem cell/cord blood banking market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The stem cell/cord blood banking global market includes revenues earned by entities by providing services such as cryopreservation and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.